ライフサイエンスコーパス: tuberculosis vaccine

1 There is an urgent need for an improved tuberculosis vaccine.

2 r many decades and in several countries as a tuberculosis vaccine.

3 nd may be of value in developing an improved tuberculosis vaccine.

4 ld facilitate the development of an improved tuberculosis vaccine.

5 ate the rational down-selection of candidate tuberculosis vaccines.

6 T cell subsets will be important for future tuberculosis vaccines.

7 uberculosis, the "gold standard" for testing tuberculosis vaccines.

8 umber, and progression in the search for new tuberculosis vaccines.

9 s accordingly widely used as a model to test tuberculosis vaccines.

10 antigens and in measuring immunogenicity of tuberculosis vaccines.

11 or molecules, which may be novel targets for tuberculosis vaccines.

12 cal relevance of a novel virus-vectored (VV) tuberculosis vaccine administered via respiratory mucosa

13 e to the rational design of a new attenuated tuberculosis vaccine and the development of new diagnost

14 arch efforts are under way to develop cattle tuberculosis vaccines and specific diagnostic reagents t

15 berculosis infection with use of a candidate tuberculosis vaccine antigen, ID93, formulated in a synt

16 culosis (TB) infection during childhood, new tuberculosis vaccines are necessary to disrupt the trans

17 Efforts to develop more effective tuberculosis vaccines are under way, but even if one is

18 his biomaterial by using the live attenuated tuberculosis vaccine bacille Calmette-Guerin (BCG).

19 In Uganda, the tuberculosis vaccine BCG is administered on the first da

20 A tuberculosis vaccine candidate consisting of a 72-kDa po

21 a expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance respo

22 ells in the lungs of mice immunized with the tuberculosis vaccine candidate Mtb72F.

23 loped a live, fully attenuated Mycobacterium tuberculosis vaccine candidate strain with two independe

24 Here, we analyze immunity induced by a live tuberculosis vaccine candidate, recombinant BCG Deltaure

25 vaccine 2 years ago, there have been no new tuberculosis vaccine candidates entering clinical testin

26 Attenuated M. tuberculosis vaccine candidates have been constructed by

27 be the development and characterization of a tuberculosis vaccine comprised of both antigen and adjuv

28 the generation of more creative diversity in tuberculosis vaccine concepts, the development of better

29 en parenterally, suggesting that respiratory tuberculosis vaccines could have an advantage in tubercu

30 e reasons, highlighting a major challenge in tuberculosis vaccine design.

31 But progress in the field of tuberculosis vaccine development has been hampered by th

32 will facilitate the global pace of clinical tuberculosis vaccine development.

33 Our approach helps fill the gap in clinical tuberculosis vaccine development.

34 se findings also have implications for human tuberculosis vaccine development.

35 Assessment of candidate tuberculosis vaccine effectiveness with this optimized m

36 However, tuberculosis vaccine efficacy in mice is critically depe

37 n BCG-primed adults with an adenovirus-based tuberculosis vaccine elicits a repertoire of memory T ce

38 and could aid in the selection of candidate tuberculosis vaccines for field efficacy testing.

39 s in a phase III trial of an investigational tuberculosis vaccine, greater baseline IFN-gamma respons

40 So far, research and development of tuberculosis vaccines has resulted in almost 20 candidat

41 ion of CD8 T cells to use with our candidate tuberculosis vaccine, ID93/glucopyranosyl lipid adjuvant

42 ical relevance of T cells induced by a novel tuberculosis vaccine in a phase 1 trial.

43 nally tested as an adjuvant within a subunit tuberculosis vaccine in neonatal mice.

44 cted MCMs, which may guide future testing of tuberculosis vaccines in nonhuman primates.

45 Whether a candidate tuberculosis vaccine induces clinically relevant protect

46 Bacillus Calmette-Guerin (BCG), the tuberculosis vaccine, is an attenuated mutant of Mycobac

47 Consequently, a successful tuberculosis vaccine may require the elicitation of sust

48 of BCG-primed CD4 T cells with heterologous tuberculosis vaccines may be best after 14 weeks of age,

49 immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus Ankara exp

50 rom a reported vaccine efficacy trial of the tuberculosis vaccine MVA85A in South Africa.

51 Groups B and D received candidate tuberculosis vaccine MVA85A.

52 e of death in AIDS patients, yet the current tuberculosis vaccine, Mycobacterium bovis bacillus Calme

53 A new postexposure tuberculosis vaccine offers greatest potential for prote

54 Evaluations of new tuberculosis vaccines should account for the possibility

55 found that Mycobacterium bovis BCG, a human tuberculosis vaccine, stimulated increased release of PG

56 Here, we tested the ability of oral M. tuberculosis vaccine strains expressing SIV Env and Gag

57 f new anti-tuberculosis drugs and attenuated tuberculosis vaccine strains.

58 Some of the most promising novel tuberculosis vaccine strategies currently under developm

59 to predict the protective efficacy of novel tuberculosis vaccines/strategies before they proceed to

60 nical trial, making it the first recombinant tuberculosis vaccine to be tested in humans.

61 e pepA and PPE18 genes, is the first subunit tuberculosis vaccine to undergo phase I clinical trials.

62 t has been directed to develop Mycobacterium tuberculosis vaccines to boost bacille Calmette-Guerin o

63 translation of preclinically promising novel tuberculosis vaccines to ultimate human applications has

64 cells/muL who received placebo in the DarDar tuberculosis vaccine trial in Tanzania, we compared the

65 cells/muL who received placebo in the DarDar tuberculosis vaccine trial in Tanzania.

66 sensus or debate on potential end points for tuberculosis vaccine trials among human immunodeficiency

67 uberculosis immunization policies and future tuberculosis vaccine trials.